Yuxuan Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3799912/publications.pdf

Version: 2024-02-01

218381 433756 10,168 30 26 31 h-index citations g-index papers 35 35 35 15632 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	5.8	3,665
2	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	6.0	1,872
3	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	13.9	451
4	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	3.3	438
5	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncology, 2019, 5, 1710.	3.4	383
6	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. Gastroenterology, 2015, 149, 1501-1510.	0.6	376
7	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Science Translational Medicine, 2015, 7, 293ra104.	5.8	372
8	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9704-9709.	3.3	317
9	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	7.7	282
10	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers. Science Translational Medicine, 2013, 5, 167ra4.	5.8	264
11	Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nature Genetics, 2014, 46, 1170-1172.	9.4	247
12	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut, 2019, 68, 663-671.	6.1	234
13	<i>TERT</i> Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. Cancer Research, 2013, 73, 7162-7167.	0.4	214
14	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	5.8	178
15	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1118.	3.4	152
16	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	2.8	118
17	Versatile genetic assembly system (VEGAS) to assemble pathways for expression in <i>S. cerevisiae</i> . Nucleic Acids Research, 2015, 43, 6620-6630.	6.5	96
18	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Medicine, 2021, 18, e1003620.	3.9	88

#	Article	lF	CITATION
19	Lavage of the Uterine Cavity for Molecular Detection of Mýllerian Duct Carcinomas: A Proof-of-Concept Study. Journal of Clinical Oncology, 2015, 33, 4293-4300.	0.8	87
20	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 2021, 148, 1014-1026.	2.3	77
21	Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer. Obstetrics and Gynecology, 2014, 124, 881-885.	1.2	44
22	High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 427-434.	1.4	38
23	Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Human Pathology, 2016, 53, 8-13.	1.1	31
24	Diagnostic potential of tumor DNA from ovarian cyst fluid. ELife, 2016, 5, .	2.8	30
25	Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 761-767.	1.4	29
26	Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Human Pathology, 2019, 85, 1-9.	1.1	28
27	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC) Journal of Clinical Oncology, 2018, 36, 3516-3516.	0.8	19
28	Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4733-4738.	3.3	12
29	Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool Journal of Clinical Oncology, 2015, 33, 518-518.	0.8	6
30	Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The	0.8	5